Guided by the mission “Rooted in Taiwan, Expanding Globally, and Enhancing Patient Accessibility, ”Yu-Jet focuses on therapies for rare and metabolic neuromuscular diseases, building a complete ecosystem from drug R&D to clinical application.

We adopt 505(b)(2) / Hybrid development models, combining regulatory strategy and clinical expert networks to accelerate development and regulatory review — achieving simultaneous submission to TFDA, EMA, and FDA.

Beyond pharmaceuticals, Yu-Jet integrates medical devices and Clinical Decision Support Systems (CDSS) to deliver comprehensive, data-driven therapeutic solutions.

• CDSS
  

  Supports clinicians in diagnosis and treatment decisions by analyzing real-world clinical data and offering personalized therapy recommendations to enhance accuracy and outcomes.

• Medical Devices
  

  Designed to assist neurological and muscular rehabilitation, complementing pharmacotherapy to improve functional recovery and quality of life.